Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months

We here report on a psychotic mother and her breast-fed infant who was treated with olanzapine. Consecutively olanzapine concentrations in the milk and plasma of the mother and in the infant were measured with tandem mass spectroscopy over a period of five month. The results show a relatively high p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychopharmacology (Oxford) 2010-01, Vol.24 (1), p.121-123
Main Authors: Whitworth, A., Stuppaeck, C., Yazdi, K., Kralovec, K., Geretsegger, C., Zernig, G., Aichhorn, W.
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - pharmacokinetics
Antipsychotic Agents - therapeutic use
Antipsychotics
Benzodiazepines - adverse effects
Benzodiazepines - pharmacokinetics
Benzodiazepines - therapeutic use
Biological and medical sciences
Breast
Breast Feeding
Breastfeeding & lactation
CYP1A2 protein
Cytochrome P-450 CYP1A2 - metabolism
Cytochrome P450
Depression, Postpartum - drug therapy
Drug therapy
Feeding
Female
Humans
Infant
Male
Mass spectroscopy
Medical sciences
Milk
Milk, Human - chemistry
Neuropharmacology
Olanzapine
Pharmacology. Drug treatments
Plasma
Plasma levels
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Psychotic Disorders - drug therapy
Psychotic Disorders - etiology
Side effects
Spectroscopic analysis
Tandem Mass Spectrometry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We here report on a psychotic mother and her breast-fed infant who was treated with olanzapine. Consecutively olanzapine concentrations in the milk and plasma of the mother and in the infant were measured with tandem mass spectroscopy over a period of five month. The results show a relatively high plasma level in the infant aged four month, probably referring to an immature hepatic transformation system, especially CYP1A2. In the following four months plasma levels of olanzapine decreased to very low, even undetectable concentrations in the infant. The infant developed normally and showed no side effects during the treatment period.
ISSN:0269-8811
1461-7285
DOI:10.1177/0269881108096504